ClinicalTrials.gg
RecruitingNCT06925984Updated Feb 2, 2026

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

An interventional study of SBRT in OligoProgressive Metastatic Disease, sponsored by Jules Bordet Institute. Recruiting at 5 sites in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Jules Bordet Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Breast Neoplasms by Jules Bordet Institute — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Jules Bordet Institute.

Planned enrollment
20th of 38
48 · median 49
Started
2025
with 2 others
No phase
6 of 42
3 open now
Registered
40th of 42
by date

Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is the 20th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 with no phase, and was the 40th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 42 studies in Breast Neoplasms by Jules Bordet Institute are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Breast Neoplasms by Jules Bordet Institute, or all of them as a file.
02

Study summary

The Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progressive disease at 1-3 extracranial metastases, which are treatable locally. The trial aims to investigate if treating these resistant metastases with SBRT (or other local treatments if SBRT is not possible) can extend the use of the current systemic therapy.

Patients will continue their existing systemic treatment while receiving SBRT on all progressive lesions. If new oligoprogression occurs, SBRT will be performed again. A new systemic treatment line will start if there is polyprogression (more than 3 lesions at once), progression of more than 6 lesions over 12 months, intracranial progression, or lesions that cannot be treated locally.

The scientific question is whether local treatment of resistant metastases can prolong the effectiveness of ongoing systemic therapy, which is particularly beneficial if the treatment is well-tolerated. The primary objective is to measure the proportion of patients surviving without changing their systemic treatment line at 6 months after SBRT.

This trial is significant for patients as it explores a method to potentially extend the duration of effective and well-tolerated treatments, offering hope for better management of metastatic breast cancer.

03

Conditions studied

  • OligoProgressive Metastatic Disease

Browse trials for

Keywords

  • Oligoprogression
  • metastatic breast cancer
  • CDK4/6 inhibitors
  • SBRT
  • SABR
  • radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status 0-2.
  • confirmed ER+/- MBC.
  • History of polymetastatic disease. Patients with genuine oligometastatic disease and 1-3 oligoprogressive lesions are only allowed if ablative therapy of all is deemed impossible.
  • Under 1st to 2nd systemic treatment line with hormonotherapy and/or CDK4/6 inhibitors for at least 6 months before progression.
  • Progressive disease at 1-3 extracranial sites.
  • Ability to treat all progressive lesions locally according to the treating radiation oncologist.

Exclusion criteria

Exclusion Criteria:

  • Second if it is not in complete remission.
  • Previous local treatment for oligoprogression under the current systemic treatment line
  • Current progression in a lesion that has been treated with SBRT before and is not amendable for surgery or radiofrequency ablation (RFA).
  • Progressive or newly diagnosed . Known brain metastases that have been nonprogressive for at least 6 months, are not an exclusion criterion.
  • Inability to continue the same ST line after local therapy (for example because of toxicity or patient refusal).
  • Pregnancy.
  • Inability to sign the .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    SBRT on the oligoprogressive metastases. Continuation of same systemic therapy.

    Radiation: SBRT

Interventions

  • RadiationSBRT

    SBRT of all oligoprogressive metastases (or other local therapy if SBRT not advisable), followed by continuation of the same systemic therapy.

06

What researchers measure

Primary outcomes

  1. NExt Systemic Treatment-Free Survival (NEST-FS)

    Time frame: At 6 months

Secondary outcomes

  1. Time to next line of systemic therapy (NEST)

    Time frame: 3 years

  2. Progression-free survival (PFS)

    Time frame: 3 years

  3. Modified Progression-free survival (mPFS)

    Defined as the survival in the absence of any of the following : (1) polyprogression (progressive disease of more than 3 lesions at the same time), (2) progression of more than 6 lesions over a 12-month rolling period, (3) intracranial progression, (4) progressing lesion that cannot be treated locally, or (5) death.

    Time frame: 3 years

  4. Chemotherapy-free survival

    Time frame: 3 years

  5. Progression-free survival after start of the subsequent line of systemic treatment (PFS2)

    Time frame: 3 year

  6. Patterns of metastatic progression

    We defined four patterns of progression: stable disease, progression on untreated pre-existing lesions, progression on treated lesions, or development of new lesions. In case of progression, it will also be determined whether it is oligoprogression (progression of 3 lesions or less) or polyprogression (progression of more than 3 lesions).

    Time frame: 3 years

  7. Overall survival (OS)

    Time frame: 3 years

  8. Acute and late physician-scored toxicity of the local intervention

    Acute and late physician-scored toxicity of the local intervention (CTCAE 5.0, Early: within 90 days; late: 90 or more days after SBRT);

    Time frame: 3 years

  9. Quality of life (QoL)

    Evolution of QoL measured with the EORTC QLQ-C30

    Time frame: 3 years

Other outcomes

  1. Correlation between (1) ctDNA burden at baseline and (2) ctDNA burden 10-12 weeks after SBRT versus the modified progression-free-survival (mPFS). NEST-FS in function of ESR1 status.

    Time frame: 3 years

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for May 2028, 30 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 30 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 13, 2025
StartActual
Oct 30, 2025
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2030
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06925984
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
Oct 30, 2025
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Feb 2, 2026

Study contacts

Robbe Van den Begin, MD PhD
Contact
robbe.vandenbegin@hubruxelles.be
+32 2 541 38 28

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion